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trality and percentages determined. RESULTS: The data reveal a 100% written di-
agnosis for all prescriptions encountered. There were more females than males
(70% vs 30%). The average number of drugs per prescription was 6.0. About 61% of
the diabetic patients were also diagnosed with hypertension. Biguanides (95%)
were the commonest oral hypoglycaemic agent prescribed while calcium channel
antagonist (60%) was the commonest antihypertensive prescribed. The average
cost of medication per prescription was GHC 40.0 (Ghana cedi) – approx $20.5 (USD),
were as the average total cost of drugs per patient for the entire year was GHC 235.2
(Ghana cedi) – approx $120 (USD) CONCLUSIONS: The study demonstrates that
most patients attending the diabetic clinic in Ho Municipal Hospital are females.
The cost of diabetic medications to patient per prescription was expectedly high,
particularly due to the high number of drugs prescribed. Most diabetic patients
have hypertension. The prescription of ACE-I therefore need to be improved to
reduce the rate of cardiovascular complication in diabetes.
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OBJECTIVES: An update of health economics analysis of type 2 diabetes mellitus
(T2DM) in adult population in Turkey was performed. The relationship between the
presence of ophthalmic complications and cost components is reported in this
presentation. METHODS: Forty centres were selected from the list of centres in
which adult T2DM patients were followed on a routine basis. These centres were
representative of the country, since they were selected by two-stage cluster sam-
pling. Medical files were reviewed for two to five years prior to the study. Item
prices were obtained from the Ministry of Health and Social Security Organization
of Turkey. Costs are calculated simply as the total of all frequency-price products
(1€  2.321 Turkish Liras; Feb 2012). RESULTS: A total of 942 patients’ data were
included in the analysis. During the previous five years, 20.8% of the patients had at
least one visit or hospital stay related with ophthalmic complications (incl. diabetic
retinopathy, cataract, glaucoma). Total annual cost were 546.60€ and 382.13€ in
patients with and without ophthalmic complications, respectively. Costs related to
treatment, laboratory tests and health care services were 397.00€, 96.19€ and 53.41€
in patients with ophthalmic complications. These cost items, however, were quite
similar in patients without ophthalmic complications and in patients with isolated
ophthalmic complications, who has no systemic complication other than ophthal-
mic complication (for treatment 277.35€ vs. 297.07€, for laboratory tests 62.09€ vs.
85.82€, and for health care services 42.69€ vs. 40.27€). CONCLUSIONS: All compo-
nents of cost increased by 25% to 55% with the presence of ophthalmic complica-
tions. But the costs were almost similar in patients without ophthalmic complica-
tions and with isolated ophthalmic complications. Thus, the increase in cost seems
to be related with the presence of concomitant systemic complications other than
ophthalmic complications alone.
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OBJECTIVES: One of the main causes of premature death and disability in diabetic
patients are amputations of lower limbs which are the result of the development of
diabetic foot syndrome (DFS). Poland belongs to countries with a high rate of am-
putation. It is believed that the high rate of amputation is caused by significantly
higher costs of DFS treatment compared to cost of amputation. Indeed, in Poland
costs of DFS hospital treatment and amputation are almost equal. To answer the
question whether the costs of DFS hospital treatment are overestimated this study
estimated diabetic foot syndrome hospitalization costs based on data collected in
the one of leading DFS treatment centers.METHODS:Data on hospitalization costs
were estimated retrospectively, based on 2011 year disease documentation of all
DFS patients treated in the Department of Gastroenterology and Metabolic Dis-
eases of the Medical University of Warsaw. Values are presented in Euros (ex-
change rate: 1 EUR4.20 PLN). RESULTS: Data on 37 patients were analyzed. Total
cost of hospitalization per patient was estimated at the amount of 1765 EUR and
was almost 2-times higher than National Health Funds (NHF) reimbursement cost
of hospitalization. However, it should be noted that most of the costs were related
to bed costs (76%) which we believe are overestimated. The second cost position
was drug costs which accounted for only 11% of total costs. Other cost positions
such as: bandage, laboratory tests, diagnostic procedures and specialized team
help (i.e. anesthesia) amounted up to 4% of total cost. CONCLUSIONS: The reim-
bursement of diabetic foot syndrome treatment seems to be rather underestimated
than overestimated. However we suppose cost data provided by the hospital de-
partment for calculation are overestimated on bed costs and underestimated at
other positions especially on diagnostic procedures and bandage costs.
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OBJECTIVES: Subclinical hypothyroidism (SH) is typically defined as asymptom-
atic, characterized by slightly increased serum thyrotropin (TSH) levels and normal
serum free thyroxine concentrations. SH is common among general population,
especially in middle-aged women most often after menopause, and it is related to
cardiovascular events. The objective of this analysis was to estimate burden of
disease of SH and it’s evolution to clinical hypothyroidism (CH) in Spain.
METHODS: The recommended methodology by WHO for burden of disease studies
was used in this analysis. Disability-adjusted life years (DALY), years of life lost
(YLL), years life with disability (YLD) and mortality related to SH and CH were
calculated based on the adjusted attributable fraction. Prevalence of risk factors in
general population as well as HR, were obtained from literature review and official
sources (CMBD, hospital mortality register). RESULTS: In Spain, the number of
patients with SH and CH was estimated at 2,767,124. Among them, TSH concentra-
tions ranged between 4.5-6.9 mUI/L in 1,949,820 patients; between 6.9-10 mUI/L in
539,988 patients and between 10-19.9 mUI/L in 278,317 patients. Every year, 12,608
cardiovascular events, 1,388 cardiac deaths and 30,550 DALY (13,124 YLL and 17,426
YLD) would be attributable to SH. SH represented between 1.6-7.3% of cardiovas-
cular DALY. CONCLUSIONS: Both the extensive socioeconomic burden of SH and
the risk of developing clinical hypothyroidism and subsequent cardiovascular
health risks among patients with SH is to be considered. This suggests the utility of
SH screening for patients with risk factors, after assessing the efficiency of screen-
ing techniques.
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OBJECTIVES: In spite of the fact that primary care physicians are recommended to
following evidence-based clinical guidelines for management of diabetes, no stud-
ies have currently evaluated the clinical and economic impact of following diabetes
guidelines in Ontario. METHODS: To assess the short- and long-term impact of
treating patients with type II diabetes according to the guidelines in South-western
Ontario, two cohorts of newly diagnosed cases in 2002 were used. The first group
included patients who were not treated according to guidelines during the diag-
nostic year and the two years after diagnosis. The second group consisted with
individuals who were not treated according to the guidelines only during the first
year but for the two subsequent years of their diagnosis they were treated to
achieve the specified targets for HbA1c, blood pressure and lipid levels according to
guidelines. The short-term impacts of intervention in clinical outcomes were cal-
culated and were used to extrapolate to 40 years horizon using the Ontario Diabetes
Economic Model (ODEM). For each cohort, the event rates for seven diabetes-re-
lated complications, the mean difference in cost, and expected quality-adjusted
life-years (QALYs) were calculated based on baseline risk and 3-years following the
intervention. RESULTS: Almost 500 individuals newly diagnosed with diabetes in
2002 were not treated according to guidelines during the first year following diag-
nosis. Of those 236 were treated according to guidelines in the second and third
year following diagnosis and 259 individuals were not (the control cohort). A small
difference has been observed between the cohorts in terms of intermediate out-
comes as well as the lifetime predicted cumulative costs, QALYs, life expectancy
and event rate. CONCLUSIONS: The results of this study indicated that treating
patients to guidelines as used by physicians did not make an impact on the short
and long-term outcomes associated with diabetes.
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OBJECTIVES: Evidence from the A1chieve study (an international, prospective, ob-
servational study of insulin analogs within routine clinical practice) suggests the
glycemic control in type 2 diabetes patients in Saudi Arabia is poor. The aim of the
current analysis was to investigate the long-term clinical and economic benefits of
a 1% reduction in HbA1c in comparison with baseline levels for type 2 diabetes
patients in the Saudi Arabian setting. METHODS: Long-term projections were
made using the published and validated CORE Diabetes Model, over a 35-year time
horizon. Patient characteristics were taken from the Saudi Arabian cohort of the
A1chieve study. At baseline, mean (SD) patient age was 51(11) years, duration of
diabetes 10(6) years and HbA1c 9.8(0)%. Following a 1% HbA1c reduction in the
active arm, HbA1c was kept constant. Captured costs included concomitant med-
ications and diabetes-related complications. Costs of antihyperglycemic treatment
and adverse events were not included. Future costs and clinical outcomes were
discounted at a rate of 3% per annum. Costs are presented in 2011 Saudi Arabian
Riyals (SAR) and converted into Euros (EUR) (SAR 1 to EUR 0.2043). RESULTS: Im-
proved glycemic control was associated with improved life expectancy by 0.71
years (10.08 versus 9.37 years). Furthermore, reduction in HbA1c was associated
with increased time free from diabetes-related complications. Direct costs were
SAR 16,084 (EUR 3,286) lower in the reduced HbA1c group (SAR 173,514 [EUR 35,449]
versus SAR 189,598 [EUR 38,735]). This was driven by savings resulting from the
reduced incidence of complications. CONCLUSIONS: Baseline glycemic control in
A1chieve type 2 diabetes patients in Saudi Arabia is sub-optimal. Improvements in
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